Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + capecitabine + levocetirizine
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of bevacizumab (an anti-angiogenic monoclonal antibody), capecitabine (a chemotherapy drug), and levocetirizine (an antihistamine). The combination was studied in a phase II clinical trial for patients with refractory metastatic colorectal cancer (mCRC). The rationale behind this combination is that levocetirizine, which has anti-inflammatory and IL-8 suppression properties, may help overcome resistance to anti-angiogenic therapy (bevacizumab). Capecitabine works by disrupting DNA and RNA synthesis in cancer cells, while bevacizumab blocks tumor angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
- Other names
- Levocetirizine with Capecitabine and BevacizumabCapecitabine, Bevacizumab, and Levocetirizine Regimen
02
Targets
HRH1 (Histamine H1 Receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)IL8 (C-X-C Motif Chemokine Ligand 8)Neuraminidase
Beyond the preview
Go deeper on bevacizumab + capecitabine + levocetirizine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + capecitabine + levocetirizine.